Spectrofluorometric Analysis of New-Generation Antidepressant Drugs in Pharmaceutical Formulations, Human Urine, and Plasma Samples

Table 3

Evaluation of accuracy and precision of the proposed method in pharmaceutical formulations.

Amount added (ng/mL)IntradayInterday
Found(%) RecoveryFound(%) Recovery
(ng/μL) ± SD1± RSD3(ng/μL) ± SD1± RSD3

SER
 10 9 . 3 8 ± 0 . 0 9 5 9 3 . 8 0 ± 1 . 8 3 8 . 5 0 ± 0 . 0 6 2 8 5 . 0 ± 2 . 7 9
 50 4 9 . 2 5 ± 0 . 0 8 9 9 8 . 5 0 ± 3 . 5 1 4 7 . 4 2 ± 0 . 1 0 6 9 4 . 8 4 ± 3 . 9 8
 100 9 8 . 9 7 ± 0 . 0 6 5 9 8 . 5 7 ± 5 . 7 1 9 8 . 9 8 ± 0 . 0 7 7 9 8 . 9 8 ± 5 . 0 4

PAR
 10 9 . 4 3 ± 0 . 0 6 6 9 4 . 3 0 ± 1 . 3 6 0 9 . 0 8 ± 0 . 1 7 6 9 0 . 8 0 ± 1 . 4 5
 50 4 9 . 0 5 ± 0 . 0 8 7 9 8 . 1 0 ± 2 . 7 3 4 9 . 0 7 ± 0 . 0 9 6 9 8 . 1 4 ± 3 . 5 5
 100 9 9 . 4 4 ± 0 . 0 6 1 9 9 . 4 4 ± 4 . 5 8 9 8 . 8 8 ± 0 . 1 3 8 9 8 . 8 8 ± 5 . 3 8

CIT
 10 9 . 8 0 ± 0 . 0 5 0 9 8 . 0 ± 1 . 6 5 8 . 3 2 ± 0 . 1 5 9 8 3 . 2 0 ± 2 . 2 6
 50 4 8 . 8 9 ± 0 . 0 7 0 9 7 . 7 8 ± 2 . 1 5 4 8 . 8 9 ± 0 . 1 1 1 9 7 . 7 8 ± 5 . 1 7
 100 9 9 . 1 7 ± 0 . 0 3 3 9 9 . 1 7 ± 5 . 1 1 9 8 . 2 2 ± 0 . 1 0 9 9 8 . 2 2 ± 6 . 4 3

VLF
 10 8 . 5 7 ± 0 . 1 0 4 8 5 . 7 0 ± 2 . 4 5 8 . 6 6 ± 0 . 1 3 0 8 6 . 6 0 ± 1 . 1 3
 50 4 8 . 5 9 ± 0 . 0 7 6 9 7 . 1 8 ± 3 . 1 2 4 7 . 6 9 ± 0 . 1 5 3 9 5 . 3 8 ± 4 . 1 7
 100 9 8 . 9 8 ± 0 . 1 2 6 9 8 . 9 8 ± 3 . 8 7 9 8 . 8 4 ± 0 . 1 1 1 9 8 . 8 4 ± 5 . 4 3

FLX
 10 8 . 7 0 ± 0 . 0 7 8 8 7 . 0 ± 1 . 3 9 7 . 9 0 ± 0 . 0 2 6 7 9 . 0 ± 2 . 9 2
 50 4 8 . 7 7 ± 0 . 1 0 3 9 7 . 5 4 ± 2 . 7 3 4 8 . 5 4 ± 0 . 1 6 5 9 7 . 0 8 ± 5 . 7 4
 100 9 8 . 6 9 ± 0 . 0 7 6 9 8 . 6 9 ± 5 . 9 1 9 7 . 7 4 ± 0 . 0 5 3 9 8 . 6 9 ± 6 . 1 9

1 A verage of six replicate determinations and their standard deviation, 2RSD: relative standard deviation.